Muaz Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muaz Ali has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Koriesh
Department of Neurology, Cleveland Clinic Florida
2 shared publications- Hong Liang
Department of Clinical Research, Cleveland Clinic Florida, Weston, FL
2 shared publications Iana Malasevskaia
Obstetrics and Gynecology, Private Clinic 'Yana Alexandr' Sana'a Yemen
2 shared publicationsSrihas Tumu
Psychiatry, California Institute of Behavioral Neurosciences & Psychology Fairfield USA
2 shared publicationsAbdaal Munir
1 shared publication- Abdaal Munir
Department of General Surgery Wirral University Teaching Hospital NHS Foundation Trust Wirral UK
1 shared publication
Latest Publications
- 28 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 555-568
Efficacy and safety of aducanumab, lecanemab, and donanemab in Alzheimer's disease: A meta-analysis of randomized controlled trials
Background: Anti-amyloid monoclonal antibodies offer a treatment strategy for early Alzheimer's disease, but their modest efficacy must be weighed against important safety concerns. Objective: To evaluate the efficacy and safety of aducanumab, lecanemab, and donanemab in randomized placebo-controlled trials. Methods: PubMed, Cochrane, and ClinicalTrials.gov were searched through February 2026 for randomized placebo-controlled trials evaluating aducanumab, lecanemab, or donanemab in early symptomatic Alzheimer's disease. Outcomes included Clinical Dementia Rating–Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), amyloid-related imaging abnormalities–edema/effusion (ARIA-E), amyloid-related imaging abnormalities–hemosiderin deposition (ARIA-H), and APOE ε4-stratified ARIA-E. Random-effects meta-analyses were performed. Results: Seven trials were included. Treatment favored intervention for ADAS-Cog (SMD −0.15, 95% CI −0.21 to −0.10), CDR-SB (MD −0.41, 95% CI −0.63 to −0.18), and MMSE (MD 0.44, 95% CI 0.03 to 0.86), although effects were small. Treatment increased ARIA-E (23.9% versus 1.9%; RR 11.65, 95% CI 9.06 to 14.99) and ARIA-H (16.8% versus 6.8%; RR 2.45, 95% CI 1.94 to 3.09). Among treated participants with APOE ε4-stratified ARIA-E data, APOE ε4 carriers had higher ARIA-E risk than non-carriers (29.3% versus 13.8%; RR 2.10, 95% CI 1.67 to 2.64). Brain-volume loss, ventricular enlargement, and treatment-related deaths were narratively identified but not pooled. Conclusions: Aducanumab, lecanemab, and donanemab showed statistically significant but small slowing of decline that may not reach patient-perceptible clinical meaningfulness. Increased ARIA risk and additional safety signals support cautious selection, imaging surveillance, and individualized risk-benefit discussions.
- 28 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 555-568
Efficacy and safety of aducanumab, lecanemab, and donanemab in Alzheimer's disease: A meta-analysis of randomized controlled trials
Background: Anti-amyloid monoclonal antibodies offer a treatment strategy for early Alzheimer's disease, but their modest efficacy must be weighed against important safety concerns. Objective: To evaluate the efficacy and safety of aducanumab, lecanemab, and donanemab in randomized placebo-controlled trials. Methods: PubMed, Cochrane, and ClinicalTrials.gov were searched through February 2026 for randomized placebo-controlled trials evaluating aducanumab, lecanemab, or donanemab in early symptomatic Alzheimer's disease. Outcomes included Clinical Dementia Rating–Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), amyloid-related imaging abnormalities–edema/effusion (ARIA-E), amyloid-related imaging abnormalities–hemosiderin deposition (ARIA-H), and APOE ε4-stratified ARIA-E. Random-effects meta-analyses were performed. Results: Seven trials were included. Treatment favored intervention for ADAS-Cog (SMD −0.15, 95% CI −0.21 to −0.10), CDR-SB (MD −0.41, 95% CI −0.63 to −0.18), and MMSE (MD 0.44, 95% CI 0.03 to 0.86), although effects were small. Treatment increased ARIA-E (23.9% versus 1.9%; RR 11.65, 95% CI 9.06 to 14.99) and ARIA-H (16.8% versus 6.8%; RR 2.45, 95% CI 1.94 to 3.09). Among treated participants with APOE ε4-stratified ARIA-E data, APOE ε4 carriers had higher ARIA-E risk than non-carriers (29.3% versus 13.8%; RR 2.10, 95% CI 1.67 to 2.64). Brain-volume loss, ventricular enlargement, and treatment-related deaths were narratively identified but not pooled. Conclusions: Aducanumab, lecanemab, and donanemab showed statistically significant but small slowing of decline that may not reach patient-perceptible clinical meaningfulness. Increased ARIA risk and additional safety signals support cautious selection, imaging surveillance, and individualized risk-benefit discussions.
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3)
Patient-Reported Outcome Measures in Acute Stroke Trials
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3)
Patient-Reported Outcome Measures in Acute Stroke Trials
- Open Access
- 22 July 2026
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 26 (1) , 35
Environmental Exposures and Stroke Risk: Converging Pathways, Unequal Burdens, and Prevention Opportunities
Purpose of Review: To synthesize recent evidence on how environmental exposures influence stroke risk, with emphasis on air pollution, thermal stress, circadian and occupational disruption, built and social environments, and selected toxicants. Recent Findings: Long-term and episodic air pollution, especially fine particulate matter with aerodynamic diameter ≤ 2.5 μm (PM₂.₅) and wildfire smoke, remain most consistently associated with stroke risk. Extreme heat combined with heat-humidity metrics is emerging as an important acute stroke trigger. Noise, artificial light at night, shift work, and long working hours show smaller but plausible associations, while greener and more walkable environments may be modestly protective. Social and structural disadvantage clusters, multiple exposures and inequities play an integrated role in risk and prevention. Summary: Environmental determinants are increasingly relevant to stroke risk. The strongest current links are realted to pollution, heat, sleep, and work disruption, as well as environmental inequity. Future research should move beyond single-exposure models toward combined-exposure as well as intervention-focused approaches.
- 22 July 2026
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 26 (1) , 35
Open AccessEnvironmental Exposures and Stroke Risk: Converging Pathways, Unequal Burdens, and Prevention Opportunities
Purpose of Review: To synthesize recent evidence on how environmental exposures influence stroke risk, with emphasis on air pollution, thermal stress, circadian and occupational disruption, built and social environments, and selected toxicants. Recent Findings: Long-term and episodic air pollution, especially fine particulate matter with aerodynamic diameter ≤ 2.5 μm (PM₂.₅) and wildfire smoke, remain most consistently associated with stroke risk. Extreme heat combined with heat-humidity metrics is emerging as an important acute stroke trigger. Noise, artificial light at night, shift work, and long working hours show smaller but plausible associations, while greener and more walkable environments may be modestly protective. Social and structural disadvantage clusters, multiple exposures and inequities play an integrated role in risk and prevention. Summary: Environmental determinants are increasingly relevant to stroke risk. The strongest current links are realted to pollution, heat, sleep, and work disruption, as well as environmental inequity. Future research should move beyond single-exposure models toward combined-exposure as well as intervention-focused approaches.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 2111-2120
In-Hospital Stroke Quality and Outcomes in the Mechanical Thrombectomy Era: Get With The Guidelines-Stroke, 2016 to 2023
BACKGROUND: In-hospital stroke is associated with delayed recognition and worse outcomes compared with community-onset stroke. Contemporary national data in the mechanical thrombectomy (MT) era are limited. METHODS: We performed a retrospective cohort study of adult ischemic stroke admissions in the Get With The Guidelines-Stroke registry from January 2016 to December 2023 (the MT era). In-hospital stroke was compared with community-onset stroke as the primary analysis. A secondary descriptive analysis comparing in-hospital patients with stroke from January 2006 to April 2012 and January 2016 to December 2023 was also performed. Primary outcomes were in-hospital mortality, discharge home, and independent ambulation at discharge. Multivariable logistic regression with generalized estimating equations accounted for within-hospital clustering and adjusted for demographics, vascular risk factors/comorbidities, and hospital characteristics. Temporal trends in MT use were assessed with the Cochran-Armitage trend test. RESULTS: Among 4 996 392 ischemic stroke admissions from 2016 to 2023, 191 355 (3.8%) were in-hospital, and 4 805 037 (96.2%) were community onset. In-hospital patients presented with greater severity (National Institutes of Health Stroke Scale score >20: 14.5% versus 7.9%; National Institutes of Health Stroke Scale score, 0–4: 43.3% versus 60.4%) had worse outcomes including higher in-hospital mortality (adjusted odds ratio, 2.27 [95% CI, 2.18–2.36]; P P P P P <0.001). Quality metrics and outcomes significantly improved in the MT era, independent of treatment modality. CONCLUSIONS: In patients with in-hospital stroke, MT rates increased over time, and improvements in quality metrics were observed regardless of treatment modality. A higher level of stroke severity and worse outcomes persists.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 2111-2120
In-Hospital Stroke Quality and Outcomes in the Mechanical Thrombectomy Era: Get With The Guidelines-Stroke, 2016 to 2023
BACKGROUND: In-hospital stroke is associated with delayed recognition and worse outcomes compared with community-onset stroke. Contemporary national data in the mechanical thrombectomy (MT) era are limited. METHODS: We performed a retrospective cohort study of adult ischemic stroke admissions in the Get With The Guidelines-Stroke registry from January 2016 to December 2023 (the MT era). In-hospital stroke was compared with community-onset stroke as the primary analysis. A secondary descriptive analysis comparing in-hospital patients with stroke from January 2006 to April 2012 and January 2016 to December 2023 was also performed. Primary outcomes were in-hospital mortality, discharge home, and independent ambulation at discharge. Multivariable logistic regression with generalized estimating equations accounted for within-hospital clustering and adjusted for demographics, vascular risk factors/comorbidities, and hospital characteristics. Temporal trends in MT use were assessed with the Cochran-Armitage trend test. RESULTS: Among 4 996 392 ischemic stroke admissions from 2016 to 2023, 191 355 (3.8%) were in-hospital, and 4 805 037 (96.2%) were community onset. In-hospital patients presented with greater severity (National Institutes of Health Stroke Scale score >20: 14.5% versus 7.9%; National Institutes of Health Stroke Scale score, 0–4: 43.3% versus 60.4%) had worse outcomes including higher in-hospital mortality (adjusted odds ratio, 2.27 [95% CI, 2.18–2.36]; P P P P P <0.001). Quality metrics and outcomes significantly improved in the MT era, independent of treatment modality. CONCLUSIONS: In patients with in-hospital stroke, MT rates increased over time, and improvements in quality metrics were observed regardless of treatment modality. A higher level of stroke severity and worse outcomes persists.
- Open Access
- 17 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5) , 432
Efficacy of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and exploratory network meta-analysis of randomized controlled trials
Background: Current therapies for Parkinson’s disease lack proven disease-modifying effects. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for type 2 diabetes, have shown potential neuroprotective properties. Their comparative efficacy in Parkinson’s disease remains unclear. Methods: A systematic search (inception–February 2026) identified randomized controlled trials evaluating GLP-1RAs in Parkinson’s disease. Pairwise and frequentist random-effects network meta-analyses were performed. The primary outcome was MDS-UPDRS Part III (ON state). Results: Five trials ( n = 708) were included. Pairwise meta-analysis showed no significant overall improvement in MDS-UPDRS Part III (MD –2.00; 95% CI –5.46 to 1.46; I² = 80.5%). Network meta-analysis demonstrated significant ON-state motor improvement with Exenatide 20 µg/day (MD –9.80; 95% CI –14.47 to –5.13) and Lixisenatide 20 µg/day (MD –3.08; 95% CI –5.31 to –0.85). No significant effects were observed for MDS-UPDRS Part III (OFF-state) or other domains (Parts I, II, and IV; ON-state). NLY01 at 5 mg/week improved PDQ-39, while NMSS showed dose-dependent divergence. Gastrointestinal adverse events were more frequent with GLP-1RAs. Conclusion: GLP-1 receptor agonists may provide dose-specific motor benefits in Parkinson’s disease, but evidence for broader clinical improvement is limited. Larger, longer-duration trials are needed.
- 17 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5) , 432
Open AccessEfficacy of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and exploratory network meta-analysis of randomized controlled trials
Background: Current therapies for Parkinson’s disease lack proven disease-modifying effects. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for type 2 diabetes, have shown potential neuroprotective properties. Their comparative efficacy in Parkinson’s disease remains unclear. Methods: A systematic search (inception–February 2026) identified randomized controlled trials evaluating GLP-1RAs in Parkinson’s disease. Pairwise and frequentist random-effects network meta-analyses were performed. The primary outcome was MDS-UPDRS Part III (ON state). Results: Five trials ( n = 708) were included. Pairwise meta-analysis showed no significant overall improvement in MDS-UPDRS Part III (MD –2.00; 95% CI –5.46 to 1.46; I² = 80.5%). Network meta-analysis demonstrated significant ON-state motor improvement with Exenatide 20 µg/day (MD –9.80; 95% CI –14.47 to –5.13) and Lixisenatide 20 µg/day (MD –3.08; 95% CI –5.31 to –0.85). No significant effects were observed for MDS-UPDRS Part III (OFF-state) or other domains (Parts I, II, and IV; ON-state). NLY01 at 5 mg/week improved PDQ-39, while NMSS showed dose-dependent divergence. Gastrointestinal adverse events were more frequent with GLP-1RAs. Conclusion: GLP-1 receptor agonists may provide dose-specific motor benefits in Parkinson’s disease, but evidence for broader clinical improvement is limited. Larger, longer-duration trials are needed.
- 17 February 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (5) , 1124-1133
Conservative Management of Perforated Diverticulitis in Adults: An Updated Systematic Review of Outcomes
Background: The management of perforated diverticulitis (PD) has shifted over the last decade, moving from aggressive surgery toward non‐operative strategies for hemodynamically stable patients. However, the safety of non‐operative treatment in cases with extraluminal air, particularly Hinchey Ia–II disease, remains debated. This systematic review evaluates the efficacy, safety, and long‐term outcomes of non‐operative management for PD and identifies radiologic predictors of treatment failure. Methods: A systematic review was conducted per PRISMA 2020 guidelines. PubMed/MEDLINE, Europe PMC, Science Direct, EBSCO Open Dissertations, ClinicalTrials.Gov , and Cochrane Library were searched for cohort studies published between 2015 and 2025. Inclusion criteria were adults with CT‐confirmed PD (Hinchey I–II) treated non‐operatively. The primary outcome was treatment success (survival without emergency surgery); secondary outcomes included recurrence, readmission, and mortality. Study quality was assessed using the Newcastle‐Ottawa Scale (NOS). Results: Twelve cohort studies comprising 25 064 patients were included. Success rates ranged from 76% to 96% for contained perforations. Distant extraluminal air (DA) was a key predictor of failure, with success falling to 10%–37% compared to > 85% for isolated pericolic air. Other risk factors included abscess diameter > 4 cm, free fluid, and age > 75 years. Mortality declined over time (from 18.6% to < 5%), coinciding with increased colorectal subspecialist involvement. Recurrence rates remained notable (16.5%–37.5%), with most occurring after one year. Conclusion: Non‐operative management is a safe, effective first‐line option for stable patients with PD, especially those with isolated pericolic air. Patients with DA or large abscesses are at higher risk of failure and require close monitoring or early intervention.
- 17 February 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (5) , 1124-1133
Conservative Management of Perforated Diverticulitis in Adults: An Updated Systematic Review of Outcomes
Background: The management of perforated diverticulitis (PD) has shifted over the last decade, moving from aggressive surgery toward non‐operative strategies for hemodynamically stable patients. However, the safety of non‐operative treatment in cases with extraluminal air, particularly Hinchey Ia–II disease, remains debated. This systematic review evaluates the efficacy, safety, and long‐term outcomes of non‐operative management for PD and identifies radiologic predictors of treatment failure. Methods: A systematic review was conducted per PRISMA 2020 guidelines. PubMed/MEDLINE, Europe PMC, Science Direct, EBSCO Open Dissertations, ClinicalTrials.Gov , and Cochrane Library were searched for cohort studies published between 2015 and 2025. Inclusion criteria were adults with CT‐confirmed PD (Hinchey I–II) treated non‐operatively. The primary outcome was treatment success (survival without emergency surgery); secondary outcomes included recurrence, readmission, and mortality. Study quality was assessed using the Newcastle‐Ottawa Scale (NOS). Results: Twelve cohort studies comprising 25 064 patients were included. Success rates ranged from 76% to 96% for contained perforations. Distant extraluminal air (DA) was a key predictor of failure, with success falling to 10%–37% compared to > 85% for isolated pericolic air. Other risk factors included abscess diameter > 4 cm, free fluid, and age > 75 years. Mortality declined over time (from 18.6% to < 5%), coinciding with increased colorectal subspecialist involvement. Recurrence rates remained notable (16.5%–37.5%), with most occurring after one year. Conclusion: Non‐operative management is a safe, effective first‐line option for stable patients with PD, especially those with isolated pericolic air. Patients with DA or large abscesses are at higher risk of failure and require close monitoring or early intervention.
- Open Access
- 26 November 2025
- Published by Xia & He Publishing in Exploratory Research and Hypothesis in Medicine
- Vol. 11 (1) , e00035
Safety and Efficacy of Stereoelectroencephalography-guided Resection and Responsive Neurostimulation in Drug-resistant Temporal Lobe Epilepsy: A Systematic Review
Temporal lobe epilepsy (TLE) is the most common focal epilepsy, with many patients developing drug-resistant epilepsy. Surgical interventions, including stereoelectroencephalography (SEEG)-guided temporal lobe resection (TLR) and SEEG-guided responsive neurostimulation (RNS), are key treatment options. This systematic review compares the efficacy and safety of these interventions in drug-resistant TLE.
- 26 November 2025
- Published by Xia & He Publishing in Exploratory Research and Hypothesis in Medicine
- Vol. 11 (1) , e00035
Open AccessSafety and Efficacy of Stereoelectroencephalography-guided Resection and Responsive Neurostimulation in Drug-resistant Temporal Lobe Epilepsy: A Systematic Review
Temporal lobe epilepsy (TLE) is the most common focal epilepsy, with many patients developing drug-resistant epilepsy. Surgical interventions, including stereoelectroencephalography (SEEG)-guided temporal lobe resection (TLR) and SEEG-guided responsive neurostimulation (RNS), are key treatment options. This systematic review compares the efficacy and safety of these interventions in drug-resistant TLE.